Azebiotics is a privately held Danish pharmaceutical company exclusively committed to discovery and development of novel antibiotics to treat multidrug-resistant infections. The company was founded in 2019 based on the serendipitous discovery of a small molecule with antimicrobial effect and is located at the Bio Innovation Institute in Copenhagen. This discovery has subsequently been transformed into the finding of a completely new class of potent antibiotics against several MDR bacteria. The company is currently exploring and developing this new class of antibiotics in collaboration with external CROs to meet the urgent medical need for new antibiotics.